基线IL-10水平预测早期RA患者阿巴西普联合MTX治疗应答
AVERT-2研究事后分析纳入446例阿巴西普联合MTX和300例安慰剂联合MTX的早期RA患者,评估基线炎症生物标志物与疾病活动度及52周治疗应答的关系。结果显示阿巴西普联合MTX显著降低47种生物标志物,高基线IL-10水平与更好的疗效应答及更少骨侵蚀相关。
要点
- 高基线IL-10水平预测阿巴西普联合MTX治疗52周时更好的临床应答
- 阿巴西普联合MTX较安慰剂联合MTX显著降低47种RA相关生物标志物
- 高基线IL-10水平与阿巴西普联合MTX治疗下更少骨侵蚀发展相关
核心结论
- 阿巴西普联合MTX治疗显著降低RA相关生物标志物,高基线IL-10水平预测更好的治疗应答。
研究设计与样本
- AVERT-2(NCT02504268)3期研究的事后探索性分析,纳入446例接受阿巴西普联合MTX和300例接受安慰剂联合MTX的DMARD初治、抗CCP抗体阳性早期RA患者,治疗56周。
主要发现
- 103种生物标志物中47种在阿巴西普联合MTX较安慰剂联合MTX显著降低,其中18种与基线疾病活动度相关。
- 高基线IL-10水平与阿巴西普联合MTX组52周时更高疗效达标概率相关(P < 0.03至P < 0.0007)。
- 高基线IL-10水平与阿巴西普联合MTX组较安慰剂联合MTX组更少骨侵蚀发展相关。
关键数值与推荐
- 高基线IL-10水平与阿巴西普联合MTX组52周疗效达标概率更高相关,P值范围P < 0.03至P < 0.0007。
临床怎么用
- 基线IL-10水平可能作为早期RA患者选择阿巴西普联合MTX治疗的预测生物标志物。
局限性
- 本文为事后探索性分析,未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Predictive biomarkers for patients with early rheumatoid arthritis (RA) are needed. This exploratory post hoc analysis investigated inflammatory biomarkers associated with baseline disease activity and biomarkers predictive of treatment response in patients who were seropositive with early RA from a phase 3 study. METHODS: The AVERT-2 study (NCT02504268) included patients who were disease-modifying antirheumatic drug naive and anti-citrullinated protein antibody positive randomized to abatacept and methotrexate (MTX) or placebo and MTX for 56 weeks. Correlations were assessed among biomarkers and disease activity, pharmacodynamic (PD) changes on disease-associated biomarkers in response to treatment, and baseline biomarkers to predict treatment response at week 52. RESULTS: In the analysis, 446 patients received abatacept and MTX and 300 received placebo and MTX. Of 103 biomarkers, 47 demonstrated a significant reduction in PD changes with abatacept and MTX versus placebo and MTX, with 18 out of 47 biomarkers showing correlations with baseline disease activity. High baseline interleukin-10 (IL-10) levels were associated with greater probability of achieving efficacy measures by week 52 in patients receiving abatacept and MTX versus placebo and MTX, consistent with a significant reduction in disease activity with abatacept and MTX (P < 0.03 to P < 0.0007). Higher baseline IL-10 levels were associated with lower bone erosive development with abatacept and MTX compared with placebo and MTX. CONCLUSION: Treatment with abatacept and MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept and MTX versus placebo and MTX across clinical outcomes. Findings suggest a well-suited mechanism of action for abatacept and MTX in patients with early RA and high baseline IL-10 levels.
引用
- Liu J, Li Y, Fu K, et al. Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. Arthritis Rheumatol. 2026. PMID: 41733109. doi:10.1002/art.70106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。